{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "STAA",
  "name": "STAAR Surgical Company",
  "url": "https://frontierpicks.com/dossiers/STAA/",
  "json_url": "https://frontierpicks.com/dossiers/STAA.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Structure broken, no dated catalyst before the ~2026-10-07 pre-release window.",
  "invalidation_trigger": "A weekly close below $22.00 turns the 2026-08-21 break of $23.50 into trend continuation and reopens the range toward the $15.59 destocking low; secondary break is the ~2026-10-07 preliminary-sales window passing with no pre-release, pushing the first post-peak China datapoint out to the November print.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "medtech-diagnostics",
    "semi-foundry-equipment",
    "m-and-a-special-situations"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Broadwood Partners holds ~31% with board seats via the 2026-01-15 cooperation agreement; Yunqi Capital 6.5%. Effective float is small and moves overshoot both ways.",
    "Revenue is effectively one product line, the EVO/EVO+ ICL. No second franchise offsets a shock to implantable-lens demand.",
    "The company issues no numeric revenue guidance; the outlook is qualitative seasonality language, leaving each quarter unanchored to a public number.",
    "China carried a higher share of trade receivables than of sales (57% vs 51% at Q1 2026); collection risk sits with third-party distributors.",
    "Alcon's $30.75/share bid was voted down 2026-01-06 and the cooperation-agreement standstill expired 2026-06-18, so a renewed approach is unconstrained but unannounced.",
    "Fiscal quarters end on a Friday (2026-04-03, 2026-07-03), so reporting dates shift year to year; all Q3 dates here are estimates."
  ],
  "body_markdown": "\n> Reference close for every level in this note: $23.14, the 2026-08-21 daily close from split/dividend-adjusted bars. 52-week high $33.34 (set May 2026); RSI(14) 43.8; the shares are down 28.7% over three months.\n\n## STAA — STAAR Surgical Company\n\n## Current Thesis\nThe level named in the prior note broke, and it broke without any new company disclosure. The sequence is short and dated: $26.18 on 2026-08-14, then a 7.8% decline to $24.15 on 2026-08-17 — the day Stifel trimmed its target from $31 to $28 and stayed at Hold, citing a \"fragile\" refractive end market in China — then a $23.14 weekly close on 2026-08-21. That is the fourth negative price event in five weeks against a strictly improving operating record: an 8.8% gap lower on 2026-07-17 after an in-line pre-announcement, a roughly flat-to-lower session on 2026-08-12 after Q2 net sales of $93.5M (up 111% year over year) and GAAP EPS of $0.16 that came in 12.6% above consensus, and now an 11.6% slide across three sessions on a rating-maintained target cut. RSI(14) went from 72.0 mid-month to 43.8 without producing an oversold washout.\n\nThe narrative leg on offer was never the company's numbers — those are measured, in three consecutive China prints. It was the second-derivative claim that a de-stocked, newly profitable, permanently-led STAAR re-rates off $181.5M of cash and investments while trading below its high. That claim has now been tested five times since 2026-07-16 and failed each time. The narrative is **dead** — narrative failed, structure broken.\n\nWhat remains is a cheap, cash-covered, single-product medtech with an unconstrained strategic acquirer in the background and no dated catalyst for roughly six weeks. That is a value argument with no narrative bid attached to it, which is a different instrument from what the name traded as in April.\n\n## Bull Case\n- **Q2 2026 (2026-08-12): net sales $93.5M, +111% YoY, with GAAP EPS $0.16 versus a -$0.34 loss in Q2 2025** — 12.6% above the consensus EPS estimate per StockStory's 2026-08-12 write-up. Gross margin 74.5% against 74.0% a year earlier; adjusted EBITDA $20.0M.\n- **China net sales $52.3M, up more than 100% YoY and 10% sequentially off Q1's $47.4M** — the third consecutive clean quarter after the 2025 destocking that took shares to a $15.59 low.\n\n- **Balance sheet covers the reset**: cash and equivalents $148.6M plus $32.9M of available-for-sale investments, $181.5M in total, with inventory at $46.8M as of the quarter ended 2026-07-03. The drawdown since May is multiple compression, not a funding event.\n- **Sell-side dispersion is wide, not uniformly negative**: as of 2026-08-17 the visible range runs UBS $19 (Sell, 2026-08-13), Stifel $28 (Hold, 2026-08-17) and Wedbush $37 (Outperform, 2026-08-13) against a $23.14 close.\n- **Strategic optionality is live but unannounced**: Alcon's $30.75/share bid was voted down 2026-01-06 and the cooperation-agreement standstill expired 2026-06-18, leaving a renewed approach unconstrained. Nothing has been announced; this is optionality, not a catalyst with a date.\n- **Governance overhang closed 2026-08-04** with Warren Foust made permanent President, CEO and director, ending the interim co-CEO structure running since February 2026.\n\n## Bear Case\n- **Price refuses to pay for the numbers.** The 2026-08-17 decline to $24.15 carried no company news — the trigger was a Hold-rated target trim. When a maintained rating moves a stock 7.8%, the marginal holder is not underwriting the operating story.\n- **Every visible estimate revision since the print is downward**: UBS $19 (from $20), Wedbush $37 (from $40), Stifel $28 (from $31). Three cuts in five sessions, no raises found.\n- **The Q3 comparison is the hardest of the year**: it laps the one-time $25.9M order booked in Q3 2025, against a China base of $52.3M that management has guided to step down \"moderately\" on seasonality — with no numeric guidance to anchor what moderate means.\n- **Growth is still one country.** Ex-China net sales were $41.2M growing 6.0% YoY in Q2; EMEA was -1% YoY (+12% excluding the Middle East). Americas +12%.\n- **Management's own framing added headwinds** at the Q2 print: uneven conditions in the overall refractive market plus tariff and currency pressure, particularly in Asia — which is what Stifel priced on 2026-08-17.\n- **The long-record holder base has no reason to defend the level**: StockStory calculated on 2026-08-17 that $1,000 invested five years earlier was worth $167.36, and the stock was up only 2.2% year-to-date at that point — roughly flat after the subsequent two sessions.\n- **Single product line.** Revenue is effectively EVO/EVO+ ICL. There is no second franchise to absorb a demand shock or a China policy change.\n\n## Setup & Price Structure\n- **The 2026-08-21 weekly close at $23.14 sits under the $23.50 shelf** and under the 200-day as it stood on 2026-07-17 ($23.80, rising at the time). No weekly close has reclaimed the failure point since.\n- **The August rally topped at $26.18 (2026-08-14) — far below the 50-day at $29.43** that the 2026-07-17 gap cut. The recovery attempt failed roughly $3 short of the broken moving average, which is a lower-high structure rather than a base.\n- **RSI(14) 43.8 is mid-range, not washed out.** A 28-point RSI decline in four sessions with no oversold reading argues the sellers were not forced.\n- **Crowding and positioning observables**: Broadwood Partners holds roughly 31% with board seats under the 2026-01-15 cooperation agreement and Yunqi Capital 6.5%, so effective float is thin and both directions overshoot. Three target cuts clustered 2026-08-13 to 2026-08-17. No earnings date inside 30 days, so there is no scheduled event to bid against. No insider purchase or issuance filing appears in the recent record to cite either way.\n- **The first observable that a base is forming** would be a weekly close back above $26.18, the level the August break started from. Absent that, the structure is a series of lower highs from the May $33.34 peak.\n\n## Catalyst Calendar (next 30 days)\n- **2026-08-24 to 2026-09-22: nothing company-confirmed.** No earnings date, no scheduled regulatory decision, no announced investor event in the public record as of 2026-08-23. Any move inside this window comes from analyst actions, China refractive-market datapoints, or a strategic approach that carries no date.\n- **~2026-10-02 (est.)** — fiscal Q3 close, implied by the Friday quarter-ends of 2026-04-03 and 2026-07-03. Outside the 30-day window.\n- **~2026-10-07 (est.)** — preliminary Q3 net sales release, pattern-based only: the company pre-released Q1 on 2026-04-08 and Q2 on 2026-07-16. Not company-confirmed.\n- **~2026-11-04 (est.)** — Q3 2026 results and call. The Q1 release landed 2026-05-13 and Q2 on 2026-08-12, so an early-to-mid November date is the estimate, not a confirmation.\n\n## What Would Change Our Mind\n- **The break has already occurred**; what is open is whether it is trend or shakeout. Trend continuation is confirmed by a weekly close below $22.00, which would extend the 2026-08-21 loss of $23.50 and reopen the range that ran to the $15.59 destocking low.\n- **The dead label comes off on a weekly close back above $26.18** — the 2026-08-14 close the August break started from — combined with a Q3 disclosure that keeps distributor inventory \"within the targeted range\" and China not far below $52.3M. Price reclaim without the fundamental line, or the line without the reclaim, is not enough.\n- **A dated catalyst that comes and goes**: if the ~2026-10-07 window passes with no preliminary sales release, the two-quarter pre-announcement pattern breaks and the first post-peak China number moves out to the November print, leaving another month with nothing to price.\n- **The bear read breaks outright** on an announced strategic approach anywhere near the $30.75 Alcon level voted down 2026-01-06, or on ex-China growth accelerating meaningfully above the 6.0% posted in Q2 — either would give the equity a driver that is not a single-country seasonal comparison.\n- **Watch the direction of revisions, not their level**: a target raise from any of UBS, Stifel or Wedbush would be the first upward revision since the Q2 print and would contradict the cluster of 2026-08-13 to 2026-08-17.\n\n## Correlation Notes\n- **China elective-procedure demand is the dominant factor.** With China at $52.3M of $93.5M in Q2, the name trades closer to a China consumer-discretionary proxy than to a US medtech multiple story; refractive surgery is a cash-pay elective purchase.\n- **Alcon is both the read-across and the acquirer.** Its refractive commentary is the cleanest third-party check on whether \"fragile refractive end market\" is company-specific or market-wide; it also bid $30.75/share, rejected 2026-01-06.\n- **FX and tariffs sit inside the P&L**, per management's own 2026-08-12 Asia commentary — RMB and yen moves feed reported net sales without any change in unit demand.\n- **Concentrated register, thin float**: Broadwood ~31% plus Yunqi 6.5% means index-flow and single-broker actions move the price more than the underlying news would suggest, as the 7.8% response to a maintained Hold on 2026-08-17 showed.\n- **No AI, rates or semiconductor linkage.** Prior theme tagging that grouped this name with semiconductor equipment does not reflect the revenue, which is a single implantable-lens franchise.",
  "first_seen": "2026-04-22",
  "last_analyzed": "2026-08-23T17:09:35+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}